206 related articles for article (PubMed ID: 31965751)
1. Race, tumor location, and disease progression among low-risk prostate cancer patients.
Mygatt JG; Cullen J; Streicher SA; Kuo HC; Chen Y; Young D; Gesztes W; Williams G; Conti G; Porter C; Stroup SP; Rice KR; Rosner IL; Burke A; Sesterhenn I
Cancer Med; 2020 Mar; 9(6):2235-2242. PubMed ID: 31965751
[TBL] [Abstract][Full Text] [Related]
2. Predicting Prostate Cancer Progression as a Function of ETS-related Gene Status, Race, and Obesity in a Longitudinal Patient Cohort.
Cullen J; Young D; Chen Y; Degon M; Farrell J; Sedarsky J; Baptiste W; Rosen P; Tolstikov V; Kiebish M; Kagan J; Srivastava S; Kuo HC; Moncur JT; Rosner IL; Narain N; Akmaev V; Petrovics G; Dobi A; McLeod DG; Srivastava S; Sesterhenn IA
Eur Urol Focus; 2018 Dec; 4(6):818-824. PubMed ID: 28753864
[TBL] [Abstract][Full Text] [Related]
3. Pathological outcome and biochemical recurrence-free survival after radical prostatectomy in African-American, Afro-Caribbean (Jamaican) and Caucasian-American men: an international comparison.
Ritch CR; Morrison BF; Hruby G; Coard KC; Mayhew R; Aiken W; Benson MC; McKiernan JM
BJU Int; 2013 Apr; 111(4 Pt B):E186-90. PubMed ID: 23107067
[TBL] [Abstract][Full Text] [Related]
4. SPINK1 expression is enriched in African American prostate cancer but is not associated with altered immune infiltration or oncologic outcomes post-prostatectomy.
Faisal FA; Kaur HB; Tosoian JJ; Tomlins SA; Schaeffer EM; Lotan TL
Prostate Cancer Prostatic Dis; 2019 Dec; 22(4):552-559. PubMed ID: 30850708
[TBL] [Abstract][Full Text] [Related]
5. Impact of Adherence to Multidisciplinary Recommendations for Adjuvant Treatment in Radical Prostatectomy Patients With High Risk of Recurrence.
Knipper S; Sadat-Khonsari M; Boehm K; Mandel P; Budäus L; Steuber T; Maurer T; Heinzer H; Schwarz R; Sauter G; Tilki D; Huland H; Graefen M
Clin Genitourin Cancer; 2020 Apr; 18(2):e112-e121. PubMed ID: 31648965
[TBL] [Abstract][Full Text] [Related]
6. Racial disparities in oncologic outcomes after radical prostatectomy: long-term follow-up.
Faisal FA; Sundi D; Cooper JL; Humphreys EB; Partin AW; Han M; Ross AE; Schaeffer EM
Urology; 2014 Dec; 84(6):1434-41. PubMed ID: 25432835
[TBL] [Abstract][Full Text] [Related]
7. Race and risk of metastases and survival after radical prostatectomy: Results from the SEARCH database.
Freedland SJ; Vidal AC; Howard LE; Terris MK; Cooperberg MR; Amling CL; Kane CJ; Aronson WJ;
Cancer; 2017 Nov; 123(21):4199-4206. PubMed ID: 28654204
[TBL] [Abstract][Full Text] [Related]
8. Prognostic Implications of Multiparametric Magnetic Resonance Imaging and Concomitant Systematic Biopsy in Predicting Biochemical Recurrence After Radical Prostatectomy in Prostate Cancer Patients Diagnosed with Magnetic Resonance Imaging-targeted Biopsy.
Gandaglia G; Ploussard G; Valerio M; Marra G; Moschini M; Martini A; Roumiguié M; Fossati N; Stabile A; Beauval JB; Malavaud B; Scuderi S; Barletta F; Afferi L; Rakauskas A; Gontero P; Mattei A; Montorsi F; Briganti A
Eur Urol Oncol; 2020 Dec; 3(6):739-747. PubMed ID: 32847747
[TBL] [Abstract][Full Text] [Related]
9. Risk of biochemical recurrence based on extent and location of positive surgical margins after robot-assisted laparoscopic radical prostatectomy.
Marcq G; Michelet A; Hannink G; Rizk J; Sauvain J; Villers A; Saffarini M; Rochat CH
BMC Cancer; 2018 Dec; 18(1):1291. PubMed ID: 30587172
[TBL] [Abstract][Full Text] [Related]
10. High Extratumoral Mast Cell Counts Are Associated with a Higher Risk of Adverse Prostate Cancer Outcomes.
Hempel Sullivan H; Heaphy CM; Kulac I; Cuka N; Lu J; Barber JR; De Marzo AM; Lotan TL; Joshu CE; Sfanos KS
Cancer Epidemiol Biomarkers Prev; 2020 Mar; 29(3):668-675. PubMed ID: 31932412
[TBL] [Abstract][Full Text] [Related]
11. Model risk scores may underestimate rate of biochemical recurrence in African American men with localized prostate cancer: a cohort analysis of over 3000 men.
Epstein M; Syed K; Danella J; Ginzburg S; Belkoff L; Tomaszewski J; Trabulsi E; Singer EA; Jacobs BL; Raman JD; Guzzo TJ; Uzzo R; Reese AC
Prostate Cancer Prostatic Dis; 2024 Jun; 27(2):257-263. PubMed ID: 37821578
[TBL] [Abstract][Full Text] [Related]
12. Do Hispanic Men Have Worse Outcomes After Radical Prostatectomy? Results From SEARCH.
Guerrios-Rivera L; Howard LE; Klaassen Z; Terris MK; Cooperberg MR; Amling CL; Kane CJ; Aronson WJ; Freedland SJ
Urology; 2021 Mar; 149():181-186. PubMed ID: 33189734
[TBL] [Abstract][Full Text] [Related]
13. Tertiary Gleason pattern in radical prostatectomy specimens is associated with worse outcomes than the next higher Gleason score group in localized prostate cancer.
Özsoy M; D'Andrea D; Moschini M; Foerster B; Abufaraj M; Mathieu R; Briganti A; Karakiewicz PI; Roupret M; Seitz C; Czech AK; Susani M; Shariat SF
Urol Oncol; 2018 Apr; 36(4):158.e1-158.e6. PubMed ID: 29288003
[TBL] [Abstract][Full Text] [Related]
14. Predictive factors associated with biochemical recurrence following radical prostatectomy for pathological T2 prostate cancer with negative surgical margins.
Aoun F; Albisinni S; Henriet B; Tombal B; Van Velthoven R; Roumeguère T
Scand J Urol; 2017 Feb; 51(1):20-26. PubMed ID: 27910728
[TBL] [Abstract][Full Text] [Related]
15. Assessing the Optimal Timing for Early Salvage Radiation Therapy in Patients with Prostate-specific Antigen Rise After Radical Prostatectomy.
Fossati N; Karnes RJ; Cozzarini C; Fiorino C; Gandaglia G; Joniau S; Boorjian SA; Goldner G; Hinkelbein W; Haustermans K; Tombal B; Shariat S; Karakiewicz PI; Montorsi F; Van Poppel H; Wiegel T; Briganti A
Eur Urol; 2016 Apr; 69(4):728-733. PubMed ID: 26497924
[TBL] [Abstract][Full Text] [Related]
16. The interaction of body mass index and race in predicting biochemical failure after radical prostatectomy.
Lee DJ; Ritch C; Desai M; Benson MC; McKiernan JM
BJU Int; 2011 Jun; 107(11):1741-7. PubMed ID: 20942835
[TBL] [Abstract][Full Text] [Related]
17. Interval to biochemical recurrence following radical prostatectomy does not affect survival in men with low-risk prostate cancer.
Bolton DM; Ta A; Bagnato M; Muller D; Lawrentschuk NL; Severi G; Syme RR; Giles GG
World J Urol; 2014 Apr; 32(2):431-5. PubMed ID: 23824175
[TBL] [Abstract][Full Text] [Related]
18. The 17-Gene Genomic Prostate Score Test as a Predictor of Outcomes in Men with Unfavorable Intermediate Risk Prostate Cancer.
Cullen J; Kuo HC; Shan J; Lu R; Aboushwareb T; Van Den Eeden SK
Urology; 2020 Sep; 143():103-111. PubMed ID: 32525077
[TBL] [Abstract][Full Text] [Related]
19. Prostate-specific antigen density predicts favorable pathology and biochemical recurrence in patients with intermediate-risk prostate cancer.
Kang HW; Jung HD; Lee JY; Kwon JK; Jeh SU; Cho KS; Ham WS; Choi YD
Asian J Androl; 2016; 18(3):480-4. PubMed ID: 26178393
[TBL] [Abstract][Full Text] [Related]
20. Timing of Androgen Deprivation Treatment for Men with Biochemical Recurrent Prostate Cancer in the Context of Novel Therapies.
Marshall CH; Chen Y; Kuo C; Cullen J; Jiang J; Rosner I; Markowski M; McLeod DG; Trock BJ; Eisenberger MA
J Urol; 2021 Sep; 206(3):623-629. PubMed ID: 34003011
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
